Search alternatives:
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
teer decrease » greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
3481
Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
-
3482
Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
-
3483
Data Sheet 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Background<p>Charged Multivesicular Body Protein 4A (CHMP4A), a member of the ESCRT-III family, plays a pivotal role in membrane remodeling and fission, with emerging evidence underscoring its significance in cancer immunotherapy. …”
-
3484
Table 1_Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center.docx
Published 2025“…TMA event-free status was reached in 15 (63%) patients. Significant improvements were observed in platelet count (63%), lactate dehydrogenase levels (76% within the first week), hemoglobin (60%), and estimated glomerular filtration rate (79%); while CH-50 levels decreased. …”
-
3485
Data Sheet 1_Genetic knockdown of DYRK1A attenuates cognitive impairment, Aβ pathology, tauopathy and neuroinflammatory responses in mouse models of AD.docx
Published 2025“…Conversely, in amyloid-beta (Aβ)-overexpressing 5xFAD mice, hippocampal DYRK1A knockdown improved short-term spatial/recognition memory and significantly increased CaMKIIα and CREB phosphorylation. …”
-
3486
-
3487
Data Sheet 2_A novel molecule targeting neutrophil-mediated B-1a cell trogocytosis attenuates sepsis-induced acute lung injury.pdf
Published 2025“…Our data showed that B-1a cell numbers and frequencies in the pleural and peritoneal cavities were significantly decreased in sepsis. …”
-
3488
Data Sheet 1_A novel molecule targeting neutrophil-mediated B-1a cell trogocytosis attenuates sepsis-induced acute lung injury.pdf
Published 2025“…Our data showed that B-1a cell numbers and frequencies in the pleural and peritoneal cavities were significantly decreased in sepsis. …”
-
3489
-
3490
-
3491
-
3492
Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx
Published 2025“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
3493
Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx
Published 2025“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
3494
Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx
Published 2025“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
3495
-
3496
-
3497
-
3498
-
3499
-
3500
Mice in the NTC and MBC-005 treatment groups were evaluated for bioluminescent signaling at 6-, 13-, and 21-days after tumor inoculation.
Published 2025“…<p>(A) Malthusian non-linear regression analysis demonstrated that the whole-body bioluminescent signal was significantly different between the different treatment groups (p < 0.0001). …”